{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:21:50Z","timestamp":1793413310738,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jneuroim.2025.578718","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T14:49:02Z","timestamp":1754750942000},"page":"578718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis"],"prefix":"10.1016","volume":"407","author":[{"given":"Shadi","family":"El-Wahsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1749-6632.1998.tb10974.x","article-title":"Antirapsyn antibodies occur commonly in patients with lupus a","volume":"841","author":"Agius","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.nmd.2005.01.010","article-title":"Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years","volume":"15","author":"Anlar","year":"2005","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/mus.21653","article-title":"Eliminating false-positive results in serum tests for neuromuscular autoimmunity","volume":"41","author":"Apiwattanakul","year":"2010","journal-title":"Muscle Nerve: Off. J. Am. Assoc. Electrodiagnos. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/cjn.2017.253","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in double seronegative myasthenia gravis: a systematic review","volume":"45","author":"Bacchi","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578718_bb0035","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0040","article-title":"Fixed cell-based assays for autoantibody detection in myasthenia gravis: a diagnostic breakthrough","volume":"38","author":"Budhram","year":"2023","journal-title":"Lancet Reg. Health."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jns.2009.03.020","article-title":"MuSK-antibody-positive myasthenia gravis in a south Asian population","volume":"284","author":"Chang","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0055","article-title":"Clinical characteristics and prognosis of anti-AChR positive myasthenia gravis combined with anti-LRP4 or anti-titin antibody","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200220","article-title":"Functional signature of LRP4 antibodies in myasthenia gravis","volume":"11","author":"Chuquisana","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0065","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2025.578718_bb0070","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0075","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin","volume":"73","author":"Cort\u00e9s-Vicente","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Cruz","year":"2015","journal-title":"Exp. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578718_bb0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Cruz","year":"2015","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578718_bb0095","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0100","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.12270","article-title":"Antibodies to clustered acetylcholine receptor: expanding the phenotype","volume":"21","author":"Devic","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nrleng.2020.09.004","article-title":"Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series","volume":"38","author":"D\u00edaz- Maroto","year":"2023","journal-title":"Neurolog\u00eda (English Edition)."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578718_bb0115","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0120","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/mus.27842","article-title":"Very late-onset limb-girdle congenital myasthenic syndrome due to GFPT1 mutation","volume":"68","author":"El-Wahsh","year":"2023","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737175.2019.1600404","article-title":"An update on thymectomy in myasthenia gravis","volume":"19","author":"Evoli","year":"2019","journal-title":"Expert. Rev. Neurother."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578718_bb0130","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0000000000002466","article-title":"3, 4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies","volume":"86","author":"Evoli","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jnnp-2017-315782","article-title":"Pattern of ocular involvement in myasthenia gravis with MuSK antibodies","volume":"88","author":"Evoli","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0150","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578718_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/08916930400021360","article-title":"The prevalence of anti-acetylcholinesterase antibodies in autoimmune disease","volume":"37","author":"Geen","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2025.578718_bb0160","first-page":"1","article-title":"Ocular myasthenia gravis: determining the predictive factors of secondary generalisation","author":"Gengadharan","year":"2024","journal-title":"Acta Neurol. Belg."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0170","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-021-00292-x","article-title":"Risk factors for generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study","volume":"11","author":"Guo","year":"2022","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","article-title":"A sensitive non-isotopic assay for acetylcholine receptor autoantibodies","volume":"364","author":"Hewer","year":"2006","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0185","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor\u2013related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2016.07.001","article-title":"Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients","volume":"298","author":"Hong","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nmd.2024.04.005","article-title":"Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series","volume":"39","author":"Horiuchi","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0205","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"51","key":"10.1016\/j.jneuroim.2025.578718_bb0210","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578718_bb0220","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Katarzyna","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0230","first-page":"1","article-title":"Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic","author":"K\u0131sabay","year":"2021","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0240","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578718_bb0245","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1468-1331.2008.02176.x","article-title":"MuSK-positive myasthenia gravis is rare in the Polish population","volume":"15","author":"Kostera-Pruszczyk","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0250","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578718_bb0255","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010031","article-title":"Minimal manifestation status and prednisone withdrawal in the MGTX trial","volume":"95","author":"Lee","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0260","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/jnnp.41.5.394","article-title":"Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications","volume":"41","author":"Lefvert","year":"1978","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578718_bb0265","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"5\u20136","key":"10.1016\/j.jneuroim.2025.578718_bb0270","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/08916930903541208","article-title":"Diagnostic use of autoantibodies in myasthenia gravis","volume":"43","author":"Leite","year":"2010","journal-title":"Autoimmunity"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0275","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0280","first-page":"38","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","author":"Li","year":"2023","journal-title":"Lancet Reg. Health\u2013Western Pacific."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.03.004","article-title":"Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures","volume":"188","author":"Li","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2025.578718_bb0290","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08916934.2011.622015","article-title":"Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors","volume":"45","author":"Luo","year":"2012","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0300","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.410410404","article-title":"Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis","volume":"41","author":"MacLennan","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2019.04.001","article-title":"False-positive acetylcholine receptor antibody results in patients without myasthenia gravis","volume":"332","author":"Maddison","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific\u2014but not total\u2014IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0315","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1988.00520260073024","article-title":"The first American case of myasthenia gravis","volume":"45","author":"Marsteller","year":"1988","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0320","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0325","doi-asserted-by":"crossref","DOI":"10.21037\/med.2018.12.04","article-title":"The pathology of the thymus in myasthenia gravis","volume":"2","author":"Marx","year":"2018","journal-title":"Mediastinum"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0330","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0335","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ana.410320419","article-title":"Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma","volume":"32","author":"Mygland","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116428","article-title":"Myasthenia gravis: historical achievements and the \u201cgolden age\u201d of clinical trials","volume":"406","author":"Nguyen-Cao","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0345","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0350","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0355","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0022-510X(85)90144-3","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis: part 3. the effect of thymectomy","volume":"69","author":"Oosterhuis","year":"1985","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0360","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"issue":"4088","key":"10.1016\/j.jneuroim.2025.578718_bb0365","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0370","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","article-title":"Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis","volume":"72","author":"Peeler","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0375","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.11.004","article-title":"Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis","volume":"218","author":"Provenzano","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0380","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1172\/JCI119048","article-title":"Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function","volume":"98","author":"Riemersma","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0385","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and low-density lipoprotein\u2013related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0390","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody\u2013positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2025.578718_bb0395","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0400","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0405","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1. 4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0410","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","volume":"144","author":"Rose","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"suppl_5","key":"10.1016\/j.jneuroim.2025.578718_bb0415","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.48.Suppl_5.40S","article-title":"Seronegative myasthenia gravis","volume":"48","author":"Sanders","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0420","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2025.578718_bb0425","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.1981.tb33739.x","article-title":"Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis","volume":"377","author":"Seybold","year":"1981","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"22","key":"10.1016\/j.jneuroim.2025.578718_bb0430","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010910","article-title":"Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm","volume":"95","author":"Shelly","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0435","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/003693306000501001","article-title":"Myasthenia gravis: a new hypothesis","volume":"5","author":"Simpson","year":"1960","journal-title":"Scott. Med. J."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0440","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578718_bb0445","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200313","article-title":"Serological markers of clinical improvement in MuSK myasthenia gravis","volume":"11","author":"Spagni","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0450","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0455","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti-K v1. 4 antibodies","volume":"21","author":"Suzuki","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0460","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early-and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578718_bb0465","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jnnp.2009.171793","article-title":"Is tongue atrophy reversible in anti-MuSK myasthenia gravis? Six-year observation","volume":"81","author":"Takahashi","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578718_bb0470","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.410100506","article-title":"Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations","volume":"10","author":"Tindall","year":"1981","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0475","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2011.09.007","article-title":"Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis","volume":"240","author":"Trakas","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0480","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.26609","article-title":"Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: a marker of relapse?","volume":"60","author":"Triplett","year":"2019","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578718_bb0485","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","article-title":"Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece","volume":"16","author":"Tsiamalos","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0490","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2014a multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578718_bb0495","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical characteristics of pediatric myasthenia: a surveillance study","volume":"132","author":"VanderPluym","year":"2013","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0500","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0505","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0510","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2023-0205","article-title":"Acetylcholine receptor and muscle-specific tyrosine kinase antibodies detection: is it time for a change?","volume":"61","author":"Villalta","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0515","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578718_bb0520","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578718_bb0525","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1212\/WNL.33.10.1276","article-title":"Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis","volume":"33","author":"Vincent","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578718_bb0530","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578718_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients","volume":"11","author":"Wang","year":"2021","journal-title":"Brain Behav."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578718_bb0540","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcad225","article-title":"Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study","volume":"117","author":"Wang","year":"2024","journal-title":"QJM"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578718_bb0545","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578718_bb0550","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","article-title":"Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China","volume":"301","author":"Yang","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0555","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213498","article-title":"Risk of false acetylcholine receptor autoantibody positivity by radioimmunoprecipitation assay in clinical practice","volume":"104","author":"Zara","year":"2025","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578718_bb0560","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2025.578718_bb0565","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578718_bb0570","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1552-6569.2009.00456.x","article-title":"MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis","volume":"21","author":"Zouvelou","year":"2011","journal-title":"J. Neuroimaging"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:50:14Z","timestamp":1779616214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825001997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":113,"alternative-id":["S0165572825001997"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578718","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578718"}}